All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
ASH 2020: Advances and challenges in the treatment of CLL
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to William Wierda, MD Anderson Cancer Center, Houston, US. We asked, Can we improve efficacy in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) by combining chimeric antigen receptor (CAR) T-cell therapy with targeted drugs?
Wierda summarizes efficacy and safety findings from the TRANSCEND CLL phase I/II study on the combination of CD19-directed CAR T-cell therapy + ibrutinib in patients with R/R CLL.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
ASH 2020: Advances and challenges in the treatment of CLL
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox